Raymond James started coverage on shares of BRAINSWAY LTD/S (NASDAQ:BWAY) in a report released on Monday, BenzingaRatingsTable reports. The brokerage issued an outperform rating and a $14.00 price target on the stock.
Several other research analysts also recently issued reports on BWAY. Cantor Fitzgerald began coverage on shares of BRAINSWAY LTD/S in a research report on Monday. They set an overweight rating and a $17.00 price objective on the stock. LADENBURG THALM/SH SH began coverage on shares of BRAINSWAY LTD/S in a research report on Monday. They set a buy rating and a $19.00 price objective on the stock. Finally, Oppenheimer began coverage on shares of BRAINSWAY LTD/S in a research report on Monday. They set an outperform rating and a $17.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, BRAINSWAY LTD/S presently has an average rating of Buy and an average target price of $16.75.
Shares of BRAINSWAY LTD/S stock opened at $10.71 on Monday. BRAINSWAY LTD/S has a 1 year low of $10.30 and a 1 year high of $12.39.
BRAINSWAY LTD/S Company Profile
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
Featured Story: What are the qualifications of a portfolio manager?
Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.